This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

McNeil Products Ltd

Foundation Park, Roxborough Way, Maidenhead, Berks, SL6 3UG
Medical Information Direct Line: 01344 864042
Medical Information e-mail: crc@its.jnj.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 22/11/2013
SPC Colpermin IBS Relief Capsules


Go to top of the page
1. Name of the medicinal product

Colpermin IBS Relief Capsules


Go to top of the page
2. Qualitative and quantitative composition

Peppermint Oil BP 0.2ml

Excipient: Arachis oil (peanut oil) BP

For the full list of excipients, see section 6.1


Go to top of the page
3. Pharmaceutical form

Sustained release enteric coated and gastro-resistant capsule, size 1. Body opaque light blue, cap opaque blue, with a blue band between body and cap.


Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

For the relief of the symptoms of Irritable Bowel Syndrome.


Go to top of the page
4.2 Posology and method of administration

For oral use. Do not chew or break the capsule.

Adults:

One capsule three times a day. This dosage may be increased to two capsules three times a day if discomfort is severe.

The capsules should be taken until symptoms resolve which would normally be within one or two weeks. The treatment can be continued for longer periods of between 2 to 3 months, when symptoms are more persistent.

Elderly:

As adult dose.

Children:

There is no experience in the use of these capsules in children under the age of 15.


Go to top of the page
4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients.


Go to top of the page
4.4 Special warnings and precautions for use

The capsules should be swallowed whole, ie not broken or chewed. Patients who already suffer from heartburn sometimes have an exacerbation of this symptom after taking Colpermin. Treatment should be discontinued in these patients.

Colpermin contains Arachis oil (peanut oil) and should not be taken by patients known to be allergic to peanut. As there is a possible relationship between allergy to peanut and allergy to Soya, patients with Soya allergy should also avoid Colpermin.

The patient should be advised to consult a doctor before use in the following circumstances:

• first presentation of these symptoms for confirmation of IBS

• aged 40 years or over and it is some time since the last attack, or the symptoms have changed

• blood has been passed from the bowel

• there is a feeling of sickness or there is vomiting

• loss of appetite or loss of weight

• paleness and tiredness

• severe constipation

• fever

• recent foreign travel

• pregnancy or planning a pregnancy or possibly pregnant

• abnormal vaginal bleeding or discharge

• difficulty or pain in passing urine

If there are new symptoms or worsening of the condition or failure to improve over two weeks, the patient should consult their doctor.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

The capsules should not be taken immediately after food. Indigestion remedies should not be taken at the same time as Colpermin.


Go to top of the page
4.6 Fertility, pregnancy and lactation

There are no adequate and well-controlled studies in pregnant women. This product should not be used during pregnancy unless the potential benefit of treatment to the mother outweighs the possible risks to the developing fetus.

It is not known whether peppermint oil or its metabolites are excreted in human milk.


Go to top of the page
4.7 Effects on ability to drive and use machines

Peppermint Oil has no influence on the ability to drive and use machines.


Go to top of the page
4.8 Undesirable effects

Adverse drug reactions (ADRs) identified during post-marketing experience with Peppermint Oil are included in the following table. The frequencies are provided according to the following convention:

Very common ≥1/10

Common ≥1/100 and <1/10

Uncommon ≥1/1,000 and <1/100

Rare ≥1/10,000, and <1/1,000

Very rare <1/10,000

Not known (cannot be estimated from the available data)

Adverse Drug Reactions Identified During Post-Marketing Experience with Peppermint Oil Frequency Category Estimated from adequately designed clinical trials or epidemiology studies

SOC

Frequency category

Adverse Event Preferred Term

Immune System Disorders

Not known

Hypersensitivity**

Nervous System Disorders

Not known

Burning sensation mucosal

Gastrointestinal System Disorders

Not known

Anorectal discomfort

Not known

Dyspepsia

Not known

Gastrooesophageal reflux

Not known

Nausea

Not known

Vomiting

** Individual intolerance as well as allergic reactions may occur. Includes erythematous rash, headache, bradycardia, muscle tremor and ataxia which may occur in conjunction with alcohol.


Go to top of the page
4.9 Overdose

The most commonly reported symptoms of overdose are severe nausea, vomiting, abdominal pain, vertigo, ataxia, drowsiness and coma.

In the event of overdosage, the stomach should be emptied by gastric lavage. Observations should be carried out with symptomatic treatment if necessary.


Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Antispasmodic and carminative.

The mode of action is local rather than systemic. The enteric coating delays opening of the capsule until it reaches the distal small bowel. Peppermint oil is then slowly released as the matrix passes along the gut. The oil exerts a local effect of colonic relaxation and a fall of intra-colonic pressure.

Pharmacological studies have demonstrated that peppermint oil exerts its inhibitory effect on gastrointestinal smooth muscle by interference with the mobilisation of calcium ions.


Go to top of the page
5.2 Pharmacokinetic properties

Not relevant.


Go to top of the page
5.3 Preclinical safety data

Not relevant.


Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

White beeswax

Arachis oil

Colloidal Silica

Gelatin, Titanium dioxide

Indigotine (E132)

Eudragit S100

Eudragit L30 D55

Triethyl citrate,

Ammonia solution 10%

Monostearin

Polyethyleneglycol 4000

Talc

Purified Water


Go to top of the page
6.2 Incompatibilities

None


Go to top of the page
6.3 Shelf life

36 months


Go to top of the page
6.4 Special precautions for storage

Store below 25°C, avoid direct sunlight.


Go to top of the page
6.5 Nature and contents of container

Aluminium foil/PVC blister pack containing 10 capsules (250μm PVC, 20μm Al).

Pack sizes: 10, 20, 60 and 100 capsules.

Not all pack sizes may be marketed.


Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements


Go to top of the page
7. Marketing authorisation holder

McNeil Products Limited

Foundation Park

Roxborough Way

Maidenhead

Berkshire

SL6 3UG

United Kingdom


Go to top of the page
8. Marketing authorisation number(s)

PL 15513/0141


Go to top of the page
9. Date of first authorisation/renewal of the authorisation

01st May 2005


Go to top of the page
10. Date of revision of the text

13th November 2013



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/1486/SPC/


Active Ingredients/Generics